ProJenX

ProJenX has deep roots in the ALS community. Named for Jenifer Estess, who founded the nonprofit Project ALS with her family and friends after receiving an ALS diagnosis at 35, the development of our ALS clinical candidate prosetin has been guided by the ALS community since Day One. At the Northeast ALS Consortium (NEALS) 2024 annual meeting, we are excited to co-present with our Community Advisory Board, which was formed at inception to fully integrate ALS lived expertise into decision-making ranging from regulatory hurdles to early phase clinical trial design. We hope you'll join us at today's virtual poster session, 2:40 - 3:40pm ET, for our poster (abstract #127) "Study PRO-101: Experience implementing an ALS community advisory board in early phase drug development." Tune in here: https://lnkd.in/gJ9vbpDN

We are excited to announce a partnership with Unlearn.AI, a pioneering technology company innovating machine learning to revolutionize medical research. This collaboration will initially implement their ALS-Digital Twin Generator into PRO-101, our Phase 1 study of prosetin in people living with ALS, and will support a more efficient and data-driven clinical development program for prosetin in ALS. Read the full press release here: https://lnkd.in/eNTMmbCe

We want to thank QurAlis for the #icebucket10 nomination - challenge accepted! We also want to "thank" our Columbia University scientific co-founders Hynek Wichterle and Arie Zask for ensuring that we thoroughly completed the challenge. Ten years later, we are grateful for crucial research funds raised for Project ALS through the #icebucketchallenge, which directly led to the development of our lead candidate prosetin for #ALS. We challenge our friends at Merck Neuroscience, Transposon Therapeutics, and Denali Therapeutics to take the plunge and continue spreading #alsawareness.

ProJenX is thrilled to announce the formation of our Clinical Advisory Board. Thank you to board Chair Angela Genge, MD, FRCP(C), eMBA and inaugural members Jinsy Andrews, MD, MSc, FAAN, Merit Cudkowicz, and Leonard van den Berg for your leadership and strategic guidance as we advance prosetin for people living with ALS. Read the press release here: https://lnkd.in/e2GcEfGH

🎉 Exciting News! 🎉 ProJenX is thrilled to announce that we have received a $1M Hoffman ALS Clinical Trial Award from The ALS Association! This significant funding will accelerate our efforts in advancing prosetin in our Phase 1C study for ALS, bringing us one step closer to improving the lives of those affected by this challenging disease. Our team is deeply grateful for this support and remains committed to advancing cutting-edge research and clinical solutions. Stay tuned for more updates coming soon as we continue to make strides in the fight against ALS. 🔗 https://lnkd.in/e-DWkbJ3 #ALS #ClinicalTrials #MAP4K #MedicalResearch #Innovation #ProJenX #ALSAssociation #prosetin

We are very pleased to share this important milestone as we continue our mission to advance promising new therapies for ALS and other neurodegenerative diseases. In the coming weeks, we will initiate enrollment in participants with ALS in Canada, The Netherlands, and later this year, with sites in the United States. Read the full release here: https://lnkd.in/gdMCkVm7

ProJenX is excited to announce that study PRO-101 has been authorized in the European Union. Following Health Canada authorization in November, this second regulatory approval will allow us to expand the global footprint of this first-in-patient study of our lead candidate prosetin, a novel, CNS-penetrant MAP4K inhibitor for ALS, to participants in Europe. Read the press release here: https://lnkd.in/eiQ56ENb #ALS #neurodegeneration

ProJenX is thrilled to announce the authorization of its clinical trial application (CTA) by Health Canada for the first-in-patient study of prosetin, a novel, CNS-penetrant MAP4K inhibitor developed for ALS. Read more here: https://lnkd.in/eKb3KMpS #ALS #neurodegeneration